Opinion

Video

Emerging Therapies for Dry Eye Disease

Author(s):

William B. Trattler, MD,Crystal Brimer, OD, FAAO

Crystal Brimer, OD, and Kelly K. Nichols, OD, MPH, PhD, discuss two treatments, AZR-MD-001 and Reproxalap, that are in the pipeline to treat patients with dry eye disease (DED).

Related Videos
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Related Content
New canalicular gel shows promise for dry eye treatment
November 13th 2024

New canalicular gel shows promise for dry eye treatment

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Intense pulsed light for treatment of dry eye disease
October 31st 2024

Intense pulsed light for treatment of dry eye disease

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

Aldeyra Therapeutics resubmits New Drug Application for reproxalap for the treatment of dry eye disease
October 3rd 2024

Aldeyra Therapeutics resubmits New Drug Application for reproxalap for the treatment of dry eye disease

Novaliq and Laboratoires Théa announce partnership and European Commission approval of ciclosporin 0.1% eye drops solution
October 2nd 2024

Novaliq and Laboratoires Théa announce partnership and European Commission approval of ciclosporin 0.1% eye drops solution

© 2024 MJH Life Sciences

All rights reserved.